Identification of a Misfolded Region in Superoxide Dismutase 1 That Is Exposed in Amyotrophic Lateral Sclerosis*

Received for publication, May 27, 2014, and in revised form, August 25, 2014. Published, JBC Papers in Press, August 27, 2014, DOI 10.1074/jbc.M114.581801

Melissa S. Rotunno†, Jared R. Auclair§, Stephanie Maniatis†, Scott A. Shaffer‡, Jeffrey Agar§, and Daryl A. Bosco§†

From the †Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, the §Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, the ¶Proteomics and Mass Spectrometry Facility, University of Massachusetts Medical School, Shrewsbury, Massachusetts 01545, and the ‡Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605

Background: Misfolded SOD1 is associated with sporadic and familial ALS.
Results: The epitope of C4F6, an antibody specific for misfolded SOD1, has been defined. Loops IV and VII in SOD1 modulate exposure of this epitope.
Conclusion: Exposure of the C4F6 epitope correlates with heightened SOD1-mediated toxicity.
Significance: Concealing the C4F6 epitope by stabilizing SOD1 loops IV and VII has therapeutic potential for ALS.

Mutations and aberrant post-translational modifications within Cu,Zn-superoxide dismutase (SOD1) cause this otherwise protective enzyme to misfold, leading to amyotrophic lateral sclerosis (ALS). The C4F6 antibody selectively binds misfolded SOD1 in spinal cord tissues from postmortem human ALS cases, as well as from an ALS-SOD1 mouse model, suggesting that the C4F6 epitope reports on a pathogenic conformation that is common to misfolded SOD1 variants. To date, the residues and structural elements that comprise this epitope have not been elucidated. Using a chemical cross-linking and mass spectrometry approach, we identified the C4F6 epitope within several ALS-linked SOD1 variants, as well as an oxidized form of WT SOD1, supporting the notion that a similar misfolded conformation is shared among pathological SOD1 proteins. Exposure of the C4F6 epitope was modulated by the SOD1 electrostatic (loop VII) and zinc binding (loop IV) loops and correlated with SOD1-induced toxicity in a primary microglia activation assay. Site-directed mutagenesis revealed Asp92 and Asp96 as key residues within the C4F6 epitope required for the SOD1-C4F6 binding interaction. We propose that stabilizing the functional loops within SOD1 and/or obscuring the C4F6 epitope are viable therapeutic strategies for treating SOD1-mediated ALS.

ALS is a quickly progressing, fatal neurodegenerative disorder that primarily targets motor neurons. The complex nature of ALS represents a hurdle in developing effective therapies for this incurable disease. A growing list of genes have been linked to ALS, where mutations in SOD1, TDP-43, FUS, and C9orf72 account for >50% of inherited or familial ALS (FALS) (1). However, much less is known about the cause(s) of sporadic ALS (SALS) that account for the majority (90%) of ALS cases (1). FALS and SALS are clinically indistinguishable, suggesting similar mechanisms are at play for both forms of this disease.

SOD1 (Cu,Zn-superoxide dismutase) represents a factor that is common to FALS and SALS. Mutations in SOD1 likely cause FALS through a gain of toxic mechanism induced by a misfolded conformation of the protein (2). Importantly, aberrant post-translational modifications cause WT SOD1 to adapt a similar misfolded conformation (3–11). These observations support an emerging, albeit controversial, hypothesis that WT SOD1 plays a pathogenic role in a subset of SALS, analogous to the role of mutant SOD1 in FALS (2). Over the past several years, conformation specific antibodies have been generated that are selective for misfolded SOD1 variants over the native, WT SOD1 protein (12–17), suggesting that the epitopes for these antibodies represent pathogenic motifs within misfolded SOD1. C4F6 is one such conformation specific monoclonal antibody and is reactive for several ALS-linked SOD1 variants (17–19) including an oxidized form of WT SOD1 (SOD1ox) that serves as a model protein for SALS (4). Importantly, C4F6 detected misfolded SOD1 species within human postmortem FALS and SALS spinal cord tissues (4, 18) and C4F6 reactivity correlated with disease progression in the spinal cords of SOD1 G93A transgenic mice (18). That C4F6 blocked the inhibitory effect of misfolded SOD1 on fast axonal transport in squid axoplasm supports the notion that the C4F6 epitope with SOD1 confers toxicity (4). Collectively, these observations indicate that the C4F6 antibody is a reliable reporter of pathogenic SOD1 species in ALS.

Despite the evidence that C4F6 is selective for pathogenic SOD1 species, very little is known about the amino acids and structural elements that comprise this epitope. Therefore, we developed a chemical cross-linking, site-directed mutagenesis and mass spectrometry approach to define the potentially toxic C4F6 epitope within misfolded SOD1 proteins. Our analyses reveal that the zinc binding (loop IV) and electrostatic (loop VII) loops within SOD1 mask the C4F6 epitope and support a model where ALS-linked mutations destabilize loop IV and VII.

*This work was supported, in whole or in part, by National Institutes of Health Grant R01NS067206. This work was also supported by funds from the ALS Therapy Alliance/CVS Pharmacy and the ALS Association (to D. A. B.).
†To whom correspondence should be addressed: Dept. of Neurology, Albert Sherman Center, A56-1057, 368 Plantation Dr., Worcester, MA 01605. Tel.: 774-455-3745; E-mail: Daryl.Bosco@umassmed.edu.
§The abbreviations used are: ALS, amyotrophic lateral sclerosis; FALS, familial ALS; SALS, sporadic ALS; SOD1, Cu,Zn-superoxide dismutase; DSP, dithiobis(succinimidyl propionate); EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; SOD1IV/VII, SOD1 lacking loops IV and VII.
Identification of a Misfolded Region in ALS-SOD1

(20, 21), thereby exposing the C4F6 epitope. In support of this model, WT SOD1 lacking loops IV and VII (SOD1IV/VII) exhibits high reactivity with C4F6 while maintaining a relatively stable tertiary fold (22, 23). Exposure of the C4F6 epitope within SOD1IV/VII directly correlates with SOD1-mediated microglia activation, indicative of enhanced SOD1 toxicity (7, 24). These findings put forth loops IV and VII, as well as the C4F6 epitope itself as therapeutic targets for SOD1-mediated ALS.

EXPERIMENTAL PROCEDURES

SOD1 Protein Expression and Purification—The pET3d vectors containing human SOD1 and SOD1IV/VII (amino acid substitutions: C6A, C111S, and C146A) were generous gifts from Dr. Jill Zitzewitz (University of Massachusetts Medical School). This vector was used to construct WT SOD1IV/VII used in this study (amino acid substitutions A66C, S111C, and C146A). The SOD1IV construct was generated by Genescript and inserted into the pET3d vector using standard cloning techniques. All mutations in this study were generated using standard site-directed mutagenesis methods. pET3d-SOD1 was expressed in BL21(DE3) PlysS cells, and protein expression was induced with 1 mM isopropyl β-D-thiogalactopyranoside (Sigma) in the presence of 200 μM copper (II) chloride (Sigma) and 200 μM zinc chloride (Sigma) when the culture reached an optical density (A600) between 0.6 and 0.8. The bacterial culture was induced for 3 h at 37 °C (wild-type SOD1) or 30 °C (FALS-linked SOD1 and SOD1IV/VII variants). Cells were harvested, and SOD1 proteins were fully purified as previously described (25). Apo SOD1 and SOD1ox were generated from purified wild-type SOD1 as previously described (4, 26). Protein concentrations for all subsequent analyses were quantified with the Pierce BCA Protein Assay kit (Thermo) and/or A280 using the appropriate extinction coefficients for monomeric SOD1.

For the mutagenesis screen in Fig. 7, SOD1IV/VII proteins were “partially purified” by ammonium sulfate precipitation of the postsonication supernatant (25). Ammonium sulfate precipitation was accomplished by adding 0.16 g of ammonium sulfate per 500 μl of bacterial lysate, agitating the mixture on a rotating platform for 15 min at 4 °C and then pelleting the precipitate by centrifugation at 13,000 rpm for 15 min. The supernatant was collected and used as the source of SOD1 protein. The samples were subjected to both native and denaturing Western analyses. These findings put forth loops IV and VII, as well as the C4F6 epitope itself as therapeutic targets for SOD1-mediated ALS.

Metal Analysis—SOD1 variants were prepared for quantitative metal analysis by dialysis with LC-MS grade water (Pierce) overnight at 4 °C. SOD1 samples at concentrations ranging from 40 to 110 μM were then subjected to an elemental analysis in technical duplicate for copper and zinc using inductively coupled plasma optical emission spectroscopy (Center for Applied Isotope Studies, University of Georgia). Postdialysis LC-MS grade water was analyzed as a buffer control and subtracted from the SOD1 samples prior to analyses.

Incubation of SOD1 Proteins with Excess Copper and Zinc—SOD1 proteins (10.75 μM) were incubated in the presence of 4-fold molar excess copper (II) chloride and zinc sulfate for 24 h at 4 °C prior to native and denaturing Western analyses (see “Immunoblots” below for details).

Immunoblots—For denaturing Western analyses, samples were diluted in 6× sample buffer (Boston Bioproducts; BP-111R). Samples were separated by PAGE with 15% Tris-acrylamide gel (unless otherwise noted) in 1% SDS, 25 mM Tris, 192 mM glycine and transferred to PVDF membrane (Millipore) in 25 mM Tris, 192 mM glycine. Membranes were blocked for 1 h in Odyssey blocking buffer (LI-COR). Primary antibodies were incubated at 4 °C overnight at the following dilutions: C4F6 (27), 1:500; C4F6, 0.3 μg/ml; anti-TNFα, 1:200 (Santa Cruz; sc-1351); and anti-Fab fragment, 1:1000 (Sigma; B0529). The blots were incubated for 1 h with fluorophore-conjugated secondary antibodies (LI-COR) prior to visualization by the Odyssey infrared imaging system (LI-COR). The Odyssey infrared imaging software (LI-COR) was used for densitometry calculations. For native Western analysis, samples were diluted 1:1 with native sample buffer (Bio-Rad; 161-0738), electrophoresed with a 7.5% Tris-acrylamide gel, and transferred to PVDF in 25 mM Tris, 192 mM glycine at 4 °C. Blots were processed as described above for denaturing Western analyses.

C4F6 Expression, Purification, and Fab Generation—A hybridoma cell line expressing the C4F6 monoclonal antibody was a generous gift from Dr. Jean-Pierre Julien (Laval University) (17). C4F6 was purified with a protein A-agarose column (Pierce) according to the manufacturer’s instructions. Purified C4F6 was buffer exchanged into 0.85% NaCl with PD10 G25 desalting columns (GE Healthcare). Fab fragments of C4F6 were generated from purified C4F6 antibody using immobilized papain (Thermo Scientific) in the presence of cysteine according to the manufacturer’s instructions.

Octet Binding Studies—Using the Octet QK automated system (Fortebio) in a 96-well format at ambient temperature, C4F6 was immobilized onto anti-mouse IgG Fc Capture Biosensor tips (Fortebio). The extent to which SOD1 bound to C4F6 was determined using curves generated by Bio-layer Interferometry, which is based on light interference on the biosensor tip in the presence of SOD1 compared with an internal reference. To generate binding curves, the C4F6-coated tips were immersed into wells containing 12, 15, or 25 μM of the respective SOD1 variant in PBS (pH 7.4) until the binding reached equilibrium (~120 s) followed by immersion into PBS-containing wells for dissociation as described (28). Dissociation constants (Kd) were determined by fitting the generated curves using the Fortebio software with a 1:1 binding model. At least...
two independent experiments were averaged for each SOD1 variant.

**Sequencing the C4F6 Antibody by Mass Spectrometry and RNA/DNA Analysis**—For mass spectrometry sequencing of the C4F6 protein, tryptic fragments of C4F6 were prepared as previously described (29) and subjected to MALDI-TOF and LC-MS/MS analyses. For MALDI-TOF/TOF, the digested peptide samples prepared above were further purified using C18 Zip Tips (Millipore) according to the manufacturer’s instructions. Samples were coapplied to the MALDI sample target with α-cyano-4-hydroxycinnamic acid matrix (5 mg/ml). Samples were analyzed with an Axima-TOF2 MALDI mass spectrometer (Shimadzu Scientific Instruments) following external calibration. The data were acquired in the positive ion reflectron mode using both collision-induced dissociation and postsource decay fragmentation modes. All spectra were processed and subjected to a database search using Mascot (Matrix Science). For MS searches, the Peptide Mass Fingerprint program was used with a peptide mass tolerance of 100 ppm. For collision-induced dissociation and postsource decay spectra, the MS/MS Ion Search program was used with a Precursor tolerance of 100 ppm and a fragment tolerance of 1.5 Da.

For LC-MS/MS analysis, tryptic peptides were reconstituted in 25 μl of 0.1% (v/v) TFA, and a 3 μl aliquot was directly loaded onto a 100-μm inner diameter custom packed trap column packed with 2 cm of 200 Å, 5μ C18AQ particles (Michrom Bioresources). Peptides were then separated on a 75 μm inner diameter analytical column packed with 25 cm of 100 Å, 5μ C18AQ (Michrom) to a gravity-pulled tip. Peptides were eluted using a Proxene Easy nanoLC (Thermo Scientific) with a linear gradient from 100% solvent A (0.1% (v/v) formic acid in 5% (v/v) acetonitrile) to 35% solvent B (0.1% formic acid in acetonitrile) over 35 min at a flow rate of 300 nl/min. The data were acquired in positive ion electrospray mode using a Thermo Scientific LTQ Orbitrap Velos Pro mass spectrometer operating in the data-dependent mode over the range m/z 350–2000. MS scans were acquired in the Orbitrap at a resolving power of 60,000 followed by 10 MS/MS spectra acquired in the LTQ ion trap. Raw data files were processed with Extract_MSN (Thermo Scientific) and were searched against the mammalian index of the NCBI nr database using Mascot (Matrix Science). The reaction was quenched by mixing samples 1:5 (v/v) with 6× reducing loading buffer and heating at 90 °C for 5 min. Samples were analyzed as described above for LC-MS/MS sequencing of the C4F6 antibody with several noted modifications. During the 120-min gradient elution, data-dependent acquisition acquired full MS scans from m/z 350–2000 in the Orbitrap Velos Pro (resolution 60,000) followed by higher energy collisional dissociation scans on the 10 most intense parent ions acquired in the Orbitrap. Parent ions with charge states of 1+, 2+, or 3+ were excluded from the analysis. For database searching, a concatenated peptide database was generated by xComb (30) containing all possible EDC- or DSP-linked tryptic peptides (allowing up to two missed cleavages) of the intermolecular interactions of SOD1 and C4F6. The raw data were searched in Proteome Discoverer 1.3 against the concatenated database, with parent tolerance of 15 ppm and fragment ion tolerance of 0.05 Da. Additionally, spectra were verified manually with the use of GPMAW 8.20 software (Lighthouse Data, Odense, Denmark). To minimize false positives, only cross-linked peptides with >50% sequence coverage were included in the list of identified cross-links.

**Microglial Activation Assays**—Primary Microglia were isolated from mouse embryonic cerebral cortices and maintained as previously described (31, 32). Microglia were plated at 100,000 cells/ml in a non-tissue culture-treated 96-well plate (Costar). Microglia were allowed to adhere to the plate for 48 h prior to treatment with SOD1 proteins. Purified recombinant SOD1 variants were added directly to culture medium of microglia at a concentration of 2.5 μM for 48 h prior to immunofluorescence and immunoblotting analyses. Where indicated, the anti-CD14 antibody (Cell Sciences; CPC401A) was added to wells at 1:200 dilution 24 h prior to SOD1 treatment. The animal protocol was approved by the institutional animal care and use committee at the University of Massachusetts Medical Center in compliance with the Animal Welfare Act, U.S. Public Health Service Policy, and the National Institute of Health guidelines. All statistics were determined with an unpaired, two-tailed t test with Welch’s correction.

**Cross-linking of SOD1 Proteins with C4F6 Fab**—For the DSP (Thermo Scientific) and d8-DSP (ProteoChem) reaction, the respective SOD1 protein (20 μM) and the Fab fragment of C4F6 (5 μM) were combined in PBS and cross-linked according to the manufacturer’s instructions. The samples were then mixed 1:5 with 6× nonreducing SDS loading buffer (Boston Bioproducts), heated at 90 °C for 5 min, and subjected to SDS-PAGE with a 10% Tris-acylamide gel followed by Coomassie Blue staining (50 μl of reaction/well) or Western analysis (as described above; 15 μl of reaction/well). Tryptic (Promega) in-gel digest was performed essentially as described (29). Extracted peptides were concentrated to 30 μl and combined 1:1 (DSP:d8-DSP) prior to mass spectrometry analysis (as described below). For EDC (Thermo Scientific), SOD1 and the Fab fragment of C4F6 were combined to final concentrations of 100 and 9 μM, respectively. EDC cross-linking was performed according to the manufacturer’s instructions. The reaction was quenched by mixing samples 1:5 (v/v) with 6× reducing loading buffer and heating at 90 °C for 5 min. Samples were analyzed as described above for DSP cross-linking.

**Identification of DSP and EDC SOD1-C4F6 Fab Cross-linked Peptides by Mass Spectrometry**—Tryptic digests were analyzed by LC-MS/MS as described above for sequencing the C4F6 antibody with several noted modifications. During the 120-min gradient elution, data-dependent acquisition acquired full MS scans from m/z 350–2000 in the Orbitrap Velos Pro (resolution 60,000) followed by higher energy collisional dissociation scans on the 10 most intense parent ions acquired in the Orbitrap. Parent ions with charge states of 1+, 2+, or 3+ were excluded from the analysis. For database searching, a concatenated concatenated peptide database was generated by xComb (30) containing all possible EDC- or DSP-linked tryptic peptides (allowing up to two missed cleavages) of the intermolecular interactions of SOD1 and C4F6. The raw data were searched in Proteome Discoverer 1.3 against the concatenated database, with parent tolerance of 15 ppm and fragment ion tolerance of 0.05 Da. Additionally, spectra were verified manually with the use of GPMAW 8.20 software (Lighthouse Data, Odense, Denmark). To minimize false positives, only cross-linked peptides with >50% sequence coverage were included in the list of identified cross-links.
Identification of a Misfolded Region in ALS-SOD1

TABLE 1

| SOD1 variant    | $K_d$ (μM) | n |
|-----------------|------------|---|
| WT SOD1         | NBD        | 5 |
| WT SOD1<sup>AV</sup> | 0.72 ± 0.24 | 2 |
| WT SOD1<sup>AV1/AVII</sup> | 0.46 ± 0.24 | 2 |
| SOD1ox          | 1.13 ± 0.60 | 4 |
| SOD1ox<sup>AV</sup> | 1.29 ± 0.35 | 2 |
| SOD1ox<sup>AV1/AVII</sup> | 0.32 ± 0.03 | 2 |
| SOD1 G93A       | 0.40 ± 0.29 | 5 |
| SOD1 G93A<sup>AV</sup> | 0.28 ± 0.05 | 2 |
| SOD1 G85R       | 3.00 ± 3.83 | 5 |
| SOD1 A4V        | 1.46 ± 0.41 | 3 |

Immunofluorescence—Cells were fixed for 5 min with 4% paraformaldehyde followed by a 30-min block in PBS, 1% BSA, 0.5% Triton (PBSAT). Primary (anti-CD11 b/c, 1:200 (Pierce; PA1–46162); and anti-α-tubulin, 1:100 (Sigma; T9026)) and secondary antibodies (fluorophore-conjugated, 1:2000 (Jackson ImmunoResearch Laboratories)) were added for 1 h at ambient temperature in PBSAT followed by nuclear staining with DAPI (1:300,000; Invitrogen; D1306) and mounting with FluorSave reagent (Fisher; D00060).

RESULTS

C4F6 Is Selective for Misfolded Forms of SOD1 over Native Wild-type SOD1—The C4F6-SOD1 binding interaction was quantified in nondenaturing conditions using the Octet system, which utilizes Bio-Layer Interferometry technology to accurately determine binding affinities (28). No binding interaction was detected between C4F6 and WT SOD1; thus, the apparent dissociation constant ($K_d$) is below the limit of detection (Table 1). C4F6 exhibited the tightest binding affinity for SOD1 G93A ($K_d = 0.40 ± 0.29$ μM), the immunogen for this antibody (17). C4F6 also recognized SOD1 A4V and G85R with $K_d$ values of 1.46 ± 0.41 and 3.00 ± 3.83 μM, respectively. Oxidation of native WT SOD1 at Cys 111 (SOD1ox) was also sufficient to produce a tight binding interaction with C4F6 ($K_d = 1.13 ± 0.60$ μM). These data suggest that C4F6 recognizes an aberrant conformation shared among multiple misfolded SOD1 variants.

Hot Spots for C4F6 Cross-linking Are Located within the Electrostatic and Zinc Binding Loops of Misfolded SOD1 Variants—We employed a chemical cross-linking strategy with native SOD1 proteins and C4F6 to identify the C4F6 epitope within misfolded SOD1. Both DSP (cross-links lysines and has a 12 Å spacer) and EDC (cross-links lysines with glutamic or aspartic acid residues and has a 0 Å spacer) were used independently to cross-link SOD1 proteins to the Fab fragment of C4F6. In the presence of DSP (Fig. 1A) and EDC (Fig. 1B), C4F6 cross-linked to all tested ALS-associated SOD1 variants and SOD1ox, but not to WT SOD1. Although the sites of ALS-linked point mutations (e.g. A4V, G85R, and G93A) and oxidation (e.g. C111) are in different regions of the tertiary structure (Fig. 2), C4F6 binding indicates that these SOD1 variants are misfolding in a similar manner.

To identify the amino acids involved in SOD1-C4F6 binding, the band corresponding to the cross-linked species (SOD1-
C4F6* was excised from a Coomassie-stained SDS-PAGE gel and subjected to tryptic digestion followed by mass spectrometry. The amino acid sequence for the C4F6 Fab fragment was determined using both mass spectrometry and RNA sequencing (see “Experimental Procedures”). To aid in DSP cross-link identification, samples were prepared with deuterium-labeled DSP (d8-DSP) in parallel, resulting in cross-linked peptides with an increased mass of 8.06 Da. Pooling both DSP and d8-DSP samples allowed for further validation of cross-linked peptides because of a charge state-dependent shift in the observed m/z of the parent ions. A representative cross-linked peptide from a pooled (d8-DSP + DSP) SOD1 G93A/C4F6 sample is illustrated in Fig. 1C (inset), where a 4.03 m/z shift was observed between the monoisotopic peaks 708.07 m/z (DSP) and 712.10 m/z (d8-DSP). This mass shift corresponds to the theoretical mass shift of a cross-linked peptide containing two direct joining the peptides, with DSP compared with d8-DSP (16.13 Da mass shift/4+ charge state = 4.03 m/z). Both parent ions, 712.10 m/z (d8-DSP) and 708.07 m/z (DSP) were subjected to MS/MS analysis and identified as residues 70–79 of SOD1 and residues 39–50 of C4F6 (Fig. 1, C and D). A representative cross-linked SOD1 G93A/C4F6 peptide from an EDC-treated sample is illustrated in Fig. 1E.

In total, 10 amino acids in SOD1 G93A were found to cross-link to C4F6, the majority of which fall in the zinc binding (loop IV, residues 49–81) and electrostatic (loop VII, residues 124–139) loops of SOD1 (Fig. 2 and Table 2). Both DSP and EDC cross-link these loop regions within SOD1 G93A to C4F6 (Fig. 2, B and C, and Table 2), demonstrating that these cross-linkers detect “hot spots” of C4F6 binding to SOD1 G93A. Interestingly, C4F6-binding hot spots within loops IV and VII are also detected for other misfolded SOD1 proteins, including apo-SOD1 and SOD1 (G85R, A4V, ox) variants (Fig. 2C and Table 2).

Misfolding of Loops IV and VII within ALS-linked SOD1 Variants Exposes the C4F6 Epitope—Because loops IV and VII within SOD1 harbor the majority of amino acids involved in C4F6 binding (Fig. 2), we hypothesized that the C4F6 epitope is located within these loops. It follows that removal of loops IV and VII within misfolded SOD1 should eliminate the C4F6-SOD1 interaction. Loop deletion constructs were engineered to test this hypothesis. SOD1IV/IV is a well folded protein as determined by x-ray crystallography (Fig. 4A) (22), NMR, protein stability (22, 23), and CD (Fig. 4B) analyses.

Surprisingly, removal of loops IV and VII within SOD1 strengthened the C4F6-SOD1 interaction. Octet (Table 1) and native Western (Fig. 4C) analyses demonstrated that removal of these loops promoted a binding interaction between WT SOD1 and C4F6. WT SOD1IV/IV and WT SOD1IV/IV bound C4F6 with $K_d$ values of $0.72 \pm 0.24$ and $0.46 \pm 0.24 \mu M$, respectively. Moreover, the affinity of SOD1ox for C4F6 increased 3-fold, from $1.13 \pm 0.60$ to $0.32 \pm 0.03 \mu M$, upon deletion of loops IV and VII. Therefore, C4F6 affinity for SOD1 proteins lacking loops IV and VII is increased relative to the respective full-length protein (Table 1). This trend is supported by native Western analyses, which show a robust increase in C4F6 reactivity for SOD1 G93A when loop IV is removed (G93A SOD1IV/IV could not be sufficiently expressed) and for both
Identification of a Misfolded Region in ALS-SOD1

TABLE 2

Amino acids that cross-link in the C4F6-SOD1 complex

| SOD1 variant     | SOD1 amino acid | C4F6 amino acid | Coverage | Efficacy | Cross-linker |
|------------------|-----------------|-----------------|----------|----------|-------------|
| SOD1 G93A 94 ± 12% | Lys70          | Lys42 HC        | >59.1    | 3/4      | DSP         |
| SOD1 G93A 94 ± 12% | Lys70          | Lys54 HC        | 66.7     | 1/4      | DSP         |
| SOD1 G93A 94 ± 12% | Lys79          | Lys42 HC        | >67.6    | 2/2      | EDC         |
| SOD1 G93A 94 ± 12% | Asp20          | Lys42 HC        | >60.0    | 4/4      | DSP         |
| SOD1 G93A 94 ± 12% | Lys121         | Lys42 HC        | 65.0     | 1/4      | DSP         |
| SOD1 G93A 94 ± 12% | Asp20          | Lys42 HC        | >55.6    | 2/4      | DSP         |
| SOD1 G93A 94 ± 12% | Asp20          | Lys42 HC        | 62.5     | 1/2      | EDC         |
| SOD1 G93A 94 ± 12% | Lys212         | Lys42 HC        | 58.3     | 1/2      | EDC         |
| SOD1 G93A 94 ± 12% | Lys212         | Lys42 HC        | 50.0     | 1/2      | EDC         |
| SOD1 G8SR 97 ± 4%  | Lys70          | Lys42 HC        | 60.0     | 1/4      | EDC         |
| SOD1 G8SR 97 ± 4%  | Lys70          | Lys42 HC        | 66.7     | 1/1      | EDC         |
| SOD1 G8SR 97 ± 4%  | Lys70          | Lys42 HC        | 55.6     | 1/1      | EDC         |
| SOD1 G8SR 97 ± 4%  | Lys70          | Lys42 HC        | 55.6     | 1/1      | EDC         |
| SOD1 A4V 94%      | Lys70          | Lys42 HC        | 54.2     | 1/1      | EDC         |
| SOD1 A4V 94%      | Lys70          | Lys42 HC        | 60.0     | 1/1      | EDC         |
| SOD1 A4V 94%      | Lys70          | Lys42 HC        | 50.0     | 1/1      | EDC         |
| SOD1 A4V 94%      | Lys43          | Lys42 HC        | 65.6     | 1/2      | DSP         |
| SOD1 A4V 94%      | Lys43          | Lys42 HC        | >51.9    | 2/2      | DSP         |
| SOD1 A4V 94%      | Lys122         | Lys42 HC        | 53.6     | 1/2      | DSP         |
| SOD1 A4V 94%      | Lys122         | Lys42 HC        | 66.7     | 1/2      | DSP         |
| SOD1 A4V 94%      | Lys122         | Lys42 HC        | >50.0    | 2/2      | DSP         |
| SOD1 OX 94%       | Lys70          | Lys45 HC        | 63.6     | 1/2      | DSP         |
| SOD1 OX 94%       | Lys70          | Lys45 HC        | >70.4    | 2/2      | DSP         |
| SOD1 OX 94%       | Lys70          | Lys45 HC        | 51.9     | 1/2      | DSP         |
| SOD1 OX 94%       | Lys70          | Lys122 LC       | 86.7     | 1/2      | DSP         |
| SOD1 OX 94%       | Lys70          | Lys45 HC        | 63.0     | 1/2      | DSP         |
| SOD1 OX 94%       | Lys70          | Lys125 HC       | 70.0     | 1/2      | DSP         |
| SOD1 OX 94%       | Lys70          | Lys125 HC       | >55.5    | 2/2      | DSP         |
| Apo WT SOD1 90%   | Lys75          | Lys45 HC        | 59.1     | 1/2      | DSP         |
| SOD1 ΔIV, VII 65% | Lys70          | Lys45 HC        | 65.6     | 1/2      | DSP         |
| SOD1 ΔIV, VII 65% | Lys70          | Lys45 HC        | 63.0     | 1/2      | DSP         |
| SOD1 ΔIV, VII 65% | Lys70          | Lys45 HC        | 65.0     | 1/2      | DSP         |

* SOD1 sequence coverage of trypsin digestion (± standard deviation, where applicable). Sequence coverage for the light and heavy chain of the C4F6 Fab fragment was found to be 90 ± 11 and 67 ± 7%, respectively. It is noted that the sequence coverage for the heavy chain is low; however, the sequence coverage of the variable region was consistently 100% (amino acids 1–120).

* Number corresponds to amino acid position in full-length SOD1.

FIGURE 3. Metal analyses reveal deficient metal coordination in ALS-linked and loop deletion SOD1 variants. The metal content of as-isolated SOD1 variants determined by inductively coupled plasma optical emission spectroscopy. Full-length SOD1 (G93A, G8SR, A4V, and ox) contain lower levels of zinc compared with WT SOD1. SOD1 (apo, WT ΔIV, G93A ΔIV, WT ΔIV/ΔVII, and ox ΔIV/ΔVII) are deficient in both copper and zinc. (apo refers to demetallated (see "Experimental Procedures"). ΔIV indicates deletion of loop IV, and ΔIV/ΔVII indicates deletion of loops IV and VII).

WT SOD1 and SOD1ox upon removal of loops IV and VII (Fig. 4C). WT SOD1ΔIV/ΔVII also cross-linked with C4F6 in the presence of DSP (Fig. 4D). Despite there being seven potential lysines available for cross-linking with DSP (Figs. 2C and 4A), cross-links were only identified at Lys122 (residue number corresponds to full-length SOD1). Lys122 is the only residue that cross-linked C4F6 in the context of full-length SOD1 G93A but was not removed by deletion of loops IV and VII (Figs. 2C and 4A). These results indicate that (i) the remaining six Lys residues in WT SOD1ΔIV/ΔVII are either not proximal to the C4F6 epitope or are not sufficiently positioned for cross-linking by DSP; (ii) the C4F6 epitope is not within, but rather is proximal to, loops IV and VII; (iii) deletion of loops IV and VII within WT SOD1 creates and/or unmasks the C4F6 epitope; and (iv) deletion of loops IV and VII in the context of misfolded ALS-linked variants further exposes the C4F6 epitope.

Exposure of the C4F6 Epitope within SOD1 Correlates with Microglial Activation—If the C4F6 epitope does indeed confer toxicity, then SOD1ΔIV/ΔVII proteins are expected to exhibit heightened toxicity. Chronic activation of microglia is evident in both ALS patients and mouse models (33, 34) and is tightly linked to motor neuron death (24, 35). Reconstituted SOD1 G93A has been shown to activate microglia in vitro and, in turn, confer toxicity to cultured motor neurons (24). We utilized this sensitive assay to determine whether exposure of the C4F6
epitope exerts a disease-relevant effect onto microglia. Cultivated primary murine microglia (>95% pure, as determined by CD11b/c-positive cells) were exposed to SOD1 for 48 h, and their activation was assessed by both cellular morphology and TNFα secretion. Treatment with all misfolded SOD1 variants employed in this study, but not WT SOD1, resulted in a similar morphological change from ramified/resting microglia to amoeboid, indicative of activation (36) (Fig. 5A). Consistent with these observations, elevated levels of secreted TNFα were detected in the media of microglia exposed to misfolded SOD1 proteins, but not WT SOD1, with the highest levels induced by WT SOD1^IV/VII (Fig. 5, B, and C). Consistent with previous studies using FALS-linked SOD1 proteins (24), the addition of an anti-CD14 antibody that competes with misfolded SOD1 for the CD14-TLR4 receptor in microglia partially suppressed SOD1-induced microglia activation for all SOD1 variants tested here (Fig. 5). We note that suppression of SOD1^G93A and WT SOD1^IV by the CD14 antibody did not achieve statistical significance; however, that an attenuation in TNFα signal was observed for all misfolded SOD1 proteins studied here indicates these proteins activate microglia through a common mechanism. Based on these data, we propose a model whereby the enhanced flexibility of loops IV and VII within ALS-linked variants (20, 21, 37) partially exposes a toxic domain that is recognized by C4F6, and this domain becomes fully exposed when these loops are removed.

Enhancing the Metal Occupancy of SOD1 Reduces Exposure of the C4F6 Epitope—To gain further insight into the relationship between the functional loops of SOD1 and the C4F6 epitope, we assessed the effect of SOD1 metal binding on C4F6 reactivity. Inductively coupled plasma optical emission spectroscopy was used to quantify the metallation status of our recombinant SOD1 proteins (Fig. 3). The WT SOD1 dimer contained ~1.9 equivalents of zinc and only 0.2 equivalents of copper, consistent with previous measurements (25). SOD1 variants exhibited a relatively reduced metallation status with respect to zinc, especially SOD1^G85R (25) (Fig. 3). The dynamics within loops IV and VII are severely perturbed in metal-free SOD1 variants (21, 38), whereas coordination of copper and especially zinc stabilizes the tertiary and quaternary structures of SOD1 (11, 39 – 41). Because the metallation status of SOD1 correlates with its propensity to misfold, it may also influence C4F6 reactivity.

In the absence of excess copper and zinc, a native Western analysis of as-isolated recombinant SOD1 variants demonstrate C4F6 reactivity in the following rank order: SOD1^G85R > G93A > A4V ≈ SOD1^ox (Fig. 6A, left panel). The relatively weak reactivity of C4F6 for SOD1^ox and A4V is consistent with the binding affinities measured by the Octet, which showed a relatively tight binding interaction for the C4F6 antigen, SOD1^G93A (Table 1). The strong reactivity for SOD1^G85R may stem from the low metallation status of this protein (Fig. 3), because an apo-form of SOD1^G93A was used to create C4F6 (17). Although the binding of C4F6 for SOD1^ox and A4V is weaker than SOD1^G93A and G85R, this antibody can still be used to detect these misfolded species with selectivity over the normally folded WT SOD1 protein (Table 1 and Figs. 1 and 6). In addition, C4F6 may exhibit enhanced reactivity for SOD1^A4V when this protein adopts a self-associated or aggregated form (18, 42).

Upon incubation with excess copper chloride (II) and zinc sulfate (Cu^{2+}/Zn^{2+}) (43), a change in the migration patterns of SOD1 variants (G93A, G85R, and A4V) was observed, consistent with an increased positive charge and change in conformation for these proteins (44). A robust decrease in C4F6 reactivity was also observed by native Western analyses when misfolded SOD1 species were incubated with metals (Fig. 6A, right panel). The addition of excess metals did not have an effect on SOD1^ox, and therefore an alternative strategy is necessary to “refold” this protein.

As expected, C4F6 did not recognize WT SOD1 in the absence or presence of excess Cu^{2+}/Zn^{2+}. However, the C4F6 epitope was exposed in full-length WT SOD1 when this protein was demetallated (Fig. 6B). As observed for the loopless constructs (Fig. 4), exposure of the C4F6 epitope in apo WT SOD1 correlated with microglia activation (Fig. 6C). C4F6 reactivity was attenuated when apo-SOD1 was incubated with excess metals (Fig. 6B); however, this attenuation was not sufficient to abolish SOD1-induced microglia activation (data not shown). Because the microglia assay is sensitive, even residual amounts of misfolded SOD1 that may have escaped remetallation are expected to induce microglia activation. An additional techni-
Identification of a Misfolded Region in ALS-SOD1

FIGURE 5. Exposure of the C4F6 epitope correlates with elevated SOD1-mediated microglial activation. Primary murine microglia were incubated with the indicated SOD1 protein (2.5 μg) for 48 h prior to analysis. A, immunofluorescence imaging with an anti-α-tubulin antibody reveals the activation status of microglia (active, closed arrows; inactive, open arrows). Preincubation with anti-CD14 (+ anti-CD14) attenuated microglial activation. Scale bar, 50 microns. B, media harvested from cells treated as in A were probed for TNFα by Western analysis (n = 4); the highest signal was observed for WT SOD1 III/VII-treated cells. TNFα secretion was attenuated for the condition with anti-CD14. SOD1 proteins added to the media were assessed by Western analysis with a pan-SOD1 antibody (bottom panel) to ensure that wells were exposed to equal amounts of protein; this antibody was less reactive for the loopless constructs. C, densitometry analysis of B, all SOD1 variants are significantly increased compared with WT SOD1 (p < 0.05) for the condition without anti-CD14; statistically significant comparisons with SOD1 III/VII (*, p < 0.05) for the condition without anti-CD14 are indicated; SOD1 variants that exhibit a significant attenuation in microglia activation in the presence of CD14 compared with the condition without anti-CD14 are indicated (#, p < 0.05).

FIGURE 6. The metallation status of SOD1 correlates with C4F6 reactivity. SOD1 was incubated for 24 h without (−) or with (+) 4-fold molar excess copper and zinc (Cu²⁺/Zn²⁺) and subjected to a native PAGE Western analysis with the C4F6 antibody. A denaturing Western blot probed with a pan-SOD1 antibody (bottom panels) serves as a loading control. A, C4F6 reactivity is reduced for SOD1 G93A, G85R, and A4V when these proteins are incubated with excess metals. B, removing metals from WT SOD1, thereby generating apo-SOD1, confers reactivity with C4F6. C4F6 reactivity is attenuated when apo-SOD1 is incubated with excess Cu²⁺/Zn²⁺. C, apo-WT SOD1 activates primary microglia as indicated by the TNFα Western analysis (gels, bottom panels; quantification, top panels; n = 2, performed as described in Fig. 5). Statistically significant comparisons are indicated (*, p < 0.05).
Amino acids Asp92 and Asp96 in SOD1 are required for C4F6 binding. Mutagenesis pinpoints key amino acids in misfolded SOD1 responsible for C4F6 reactivity. A, Western analyses of SOD1^IV/VI/IV with the indicated mutations (residue number corresponds to full-length SOD1). Pan-SOD1 (green) and C4F6 (red) antibodies were employed to assess partially purified SOD1 expression and reactivity with C4F6, respectively (control = WT SOD1^IV/VI). Native Western analysis (top panels) shows a loss of C4F6 reactivity for the following proteins: D90A/D92A/V94A, D96A/S98A/D101A, V97A/I99A/D101A, and F45A/V47A. Denaturing Western analysis (SDS) of SOD1^IV/VI/IV variants reveal a loss of C4F6 reactivity for the triple mutations V97A/I99A/D101A, D90A/D92A/V94A, and D96A/S98A/D101A. B and D, the same analyses described in A demonstrate the D92A and D96A mutations induce a loss of C4F6 reactivity for SOD1^IV/VI (B) and full-length ALS-linked SOD1 variants (D) under both native and denaturing conditions. Control indicates WT SOD1^IV/VI/IV as indicated by CD spectroscopy. MRE, mean residue ellipticity; Control, WT SOD1^IV/VI/IV. C, ALS-linked proteins containing the D96A mutation retain the ability to activate microglia as indicated by TNFα Western analysis (bottom panel, performed as described in Fig. 5). Quantification of TNFα is displayed above. Statistical significant comparisons between ALS-linked SOD1 variants and their D96A counterparts are indicated (*, p < 0.05; n = 4). F, the location of amino acids Asp92 and Asp96 mapped onto SOD1^IV/VI (Protein Data Bank code 4BCZ).
Identification of a Misfolded Region in ALS-SOD1

The structural conformation(s) within misfolded SOD1 that trigger toxic events in ALS have not been defined. Based on the following observations, we posit that the C4F6 epitope represents a misfolded conformation that confers toxicity. First, C4F6 reactivity has been demonstrated in both SALS (4) and FALS human spinal cord sections (18). Second, C4F6 preferentially binds both FALS-linked SOD1 (4, 17–19) and aberrantly modified WT SOD1 (4) proteins (Table 1). Third, C4F6 blocks the toxic effect of SOD1 derived from SALS human spinal cord tissues in an axonal transport assay (4). Fourth, C4F6 reactivity within spinal cord sections of SOD1 G93A transgenic mice directly correlates with disease progression (18).

In the present study, we quantified the dissociation constants between C4F6 and FALS-linked SOD1 mutants and demonstrated binding for all FALS-linked SOD1 variants tested. Although C4F6 exhibited the lowest relative affinity for SOD1 A4V (Table 1 and Fig. 6), this antibody is still able to detect this variant, which is both aggressive and common in North America, with clear selectivity over normally folded WT SOD1. Further, Brotherton et al. (18) detected C4F6-positive inclusions in human FALS spinal cord tissues expressing SOD1 A4V, suggesting that C4F6 reactivity is enhanced for aggregated forms of SOD1 A4V.

Information regarding the residues and structural elements that comprise the C4F6 epitope have been lacking (4). Our chemical cross-linking and mass spectrometry strategy developed here was employed to define the C4F6 epitope, leading us to identify critical residues and structural elements relevant to the toxic ALS-phenotypes induced by misfolded SOD1 in vivo.

Importantly, we show it is possible to convert the properly folded WT SOD1 to a microglia-activating, misfolded conformation recognized by C4F6 by stripping SOD1 of both copper and zinc (Fig. 6). We further show the ability to revert the misfolded conformation of SOD1 to a more “WT-like” structure, as demonstrated by the reduced accessibility of the C4F6 epitope in misfolded SOD1 upon incubation with excess metals (Fig. 6). A similar outcome could potentially be achieved with chemical chaperones, which have been used to mitigate the misfolding and toxicity of other amyloidogenic proteins (52). Either with small molecules or alternative approaches, our results advocate for concealing the C4F6 epitope and/or stabilizing loops IV and VII as rational therapeutic strategies for SOD1-mediated ALS.

Acknowledgments—We are grateful to Dr. J. Zitzewitz (University of Massachusetts Medical School) for assistance with C4F6 sequencing; Dr. K. Boggio and all members of the Bosco lab for helpful discussion.
REFERENCES

1. Reedharian, J., and Brown, R. H., Jr. (2013) Amyotrophic lateral sclerosis: problems and prospects. *Ann. Neurol.* 74, 309–316

2. Rotruno, M. S., and Bosco, D. A. (2013) An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. *Front Cell Neurosci.* 7, 253

3. Auclair, J. R., Johnson, J. L., Liu, Q., Salisbury, J. P., Rotruno, M. S., Petsko, G. A., Ringe, D., Brown, R. H., Jr., Bosco, D. A., and Agar, J. N. (2013) Post-translational modification by cysteine protects Cu/Zn-superoxide dismutase from oxidative damage. *Biochemistry* 52, 6137–6144

4. Bosco, D. A., Morfini, G., Karabacak, N. M., Song, Y., Gros-Louis, F., Pasinelli, P., Goolsby, H., Fontaine, B. A., Lemay, N., McKenna-Yasek, D., Frosch, M. P., Agar, J. N., Julien, J. P., Brady, S. T., and Brown, R. H., Jr. (2010) Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. *J. Neuropathol. Extrapol.* 13, 1396–1403

5. Fujiwara, N., Nakano, M., Kato, S., Yoshihara, D., Ookawara, T., Eguchi, H., Taniguchi, N., and Suzuki, K. (2007) Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. *J. Biol. Chem.* 282, 35933–35944

6. Chen, X., Shang, H., Qiu, X., Fujiwara, N., Cui, L., Li, X. M., Gao, T. M., and Kong, J. (2012) Oxidative modification of cysteine 111 promotes disulfide bond-independent aggregation of SOD1. *Neurochem. Res.* 37, 835–845

7. Ezzi, S. A., Uruishihi, M., and Julien, J. P. (2007) Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. *J. Neurochem.* 102, 170–178

8. Banci, L., Bertini, I., Boca, M., Calderone, V., Cantini, F., Girotto, S., and Vieru, M. (2009) Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants. *Proc. Natl. Acad. Sci. U.S.A.* 106, 6980–6985

9. Ding, F., and Dokholyan, N. V. (2008) Dynamical roles of metal ions and the disulfide bond in Cu, Zn superoxide dismutase folding and aggregation. *Proc. Natl. Acad. Sci. U.S.A.* 105, 19696–19701

10. Durazo, A., Shaw, B. F., Chattopadhyay, M., Faull, K. F., Nersissian, A. M., Valentine, J. S., and Whitelegge, J. P. (2009) Metal-free superoxide dismutase-1 and three different ALS variants share a similar partially unfolded β-barrel at physiological temperature. *J. Biol. Chem.* 284, 34382–34389

11. Arnesano, F., Banci, L., Bertini, I., Martinelli, M., Furukawa, Y., and O’Halloran, T. V. (2004) The unusually stable quaternary structure of human CuZn-superoxide dismutase 1 is controlled by both metal occupancy and disulphide status. *J. Biol. Chem.* 279, 47998–48003

12. Forsberg, K., Jonsson, P. A., Andersen, P. M., Bergemalm, D., Graffmo, K. S., Hultdin, M., Jacobsson, J., Rosquist, R., Marklund, S. L., and Brändén, C. J. D., Boylan, K., and Glass, J. D. (2012) Localization of a toxic form of SOD1 in ALS. *Proc. Natl. Acad. Sci. U.S.A.* 109, 6188–6199

13. Fujisawa, T., Homma, K., Nishitoh, H., and Ichijo, H. (2012) A novel monoclonal antibody reveals a common pathogenic pathway in familial amyotrophic lateral sclerosis. *Science* 330, 1472–1478

14. Kong, J. (2012) Oxidative modification of cysteine 111 promotes disulfide bond formation and aggregation. *Proc. Natl. Acad. Sci. U.S.A.* 109, 20117–20120

15. Fujiwara, N., Nakano, M., Kato, S., Yoshihara, D., Ookawara, T., Eguchi, H., Taniguchi, N., and Suzuki, K. (2007) Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. *J. Biol. Chem.* 282, 35933–35944

16. Chen, X., Shang, H., Qiu, X., Fujiwara, N., Cui, L., Li, X. M., Gao, T. M., and Kong, J. (2012) Oxidative modification of cysteine 111 promotes disulfide bond-independent aggregation of SOD1. *Neurochem. Res.* 37, 835–845

17. Ezzi, S. A., Uruishihi, M., and Julien, J. P. (2007) Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. *J. Neurochem.* 102, 170–178

18. Banci, L., Bertini, I., Boca, M., Calderone, V., Cantini, F., Girotto, S., and Vieru, M. (2009) Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants. *Proc. Natl. Acad. Sci. U.S.A.* 106, 6980–6985

19. Ding, F., and Dokholyan, N. V. (2008) Dynamical roles of metal ions and the disulfide bond in Cu, Zn superoxide dismutase folding and aggregation. *Proc. Natl. Acad. Sci. U.S.A.* 105, 19696–19701

20. Durazo, A., Shaw, B. F., Chattopadhyay, M., Faull, K. F., Nersissian, A. M., Valentine, J. S., and Whitelegge, J. P. (2009) Metal-free superoxide dismutase-1 and three different ALS variants share a similar partially unfolded β-barrel at physiological temperature. *J. Biol. Chem.* 284, 34382–34389

21. Arnesano, F., Banci, L., Bertini, I., Martinelli, M., Furukawa, Y., and O’Halloran, T. V. (2004) The unusually stable quaternary structure of human CuZn-superoxide dismutase 1 is controlled by both metal occupancy and disulphide status. *J. Biol. Chem.* 279, 47998–48003

22. Forsberg, K., Jonsson, P. A., Andersen, P. M., Bergemalm, D., Graffmo, K. S., Hultdin, M., Jacobsson, J., Rosquist, R., Marklund, S. L., and Brändén, C. J. D., Boylan, K., and Glass, J. D. (2012) Localization of a toxic form of SOD1 in ALS. *Proc. Natl. Acad. Sci. U.S.A.* 109, 6188–6199

23. Fujisawa, T., Homma, K., Nishitoh, H., and Ichijo, H. (2012) A novel monoclonal antibody reveals a common pathogenic pathway in familial amyotrophic lateral sclerosis. *Science* 330, 1472–1478

24. Kong, J. (2012) Oxidative modification of cysteine 111 promotes disulfide bond formation and aggregation. *Proc. Natl. Acad. Sci. U.S.A.* 109, 20117–20120

25. Fujiwara, N., Nakano, M., Kato, S., Yoshihara, D., Ookawara, T., Eguchi, H., Taniguchi, N., and Suzuki, K. (2007) Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. *J. Biol. Chem.* 282, 35933–35944

26. Chen, X., Shang, H., Qiu, X., Fujiwara, N., Cui, L., Li, X. M., Gao, T. M., and Kong, J. (2012) Oxidative modification of cysteine 111 promotes disulfide bond-independent aggregation of SOD1. *Neurochem. Res.* 37, 835–845
38. Elam, J. S., Taylor, A. B., Strange, R., Antonyuk, S., Doucette, P. A., Rodriguez, J. A., Hasnain, S. S., Hayward, L. J., Valentine, J. S., Yeates, T. O., and Hart, P. J. (2003) Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat. Struct. Biol. 10, 461–467
39. Banci, L., Bertini, I., Cramaro, F., Del Conte, R., and Viezzoli, M. S. (2003) Solution structure of Apo Cu,Zn superoxide dismutase: role of metal ions in protein folding. Biochemistry 42, 9543–9553
40. Stathopulos, P. B., Rumfeldt, J. A., Scholz, G. A., Irani, R. A., Frey, H. E., Hallewell, R. A., Lepock, J. R., and Meiering, E. M. (2003) Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc. Natl. Acad. Sci. U.S.A. 100, 7021–7026
41. Lynch, S. M., Boswell, S. A., and Colón, W. (2004) Kinetic stability of Cu/Zn superoxide dismutase is dependent on its metal ligands: implications for ALS. Biochemistry 43, 16525–16531
42. Redler, R. L., Fee, L., Fay, J. M., Caplow, M., and Dokholyan, N. V. (2014) Non-native soluble oligomers of Cu/Zn superoxide dismutase (SOD1) contain a conformational epitope linked to cytotoxicity in amyotrophic lateral sclerosis (ALS). Biochemistry 53, 2423–2432
43. Auclair, J. R., Boggio, K. J., Petsko, G. A., Ringo, D., and Agar, J. N. (2010) Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 107, 21394–21399
44. Tiwari, A., Liba, A., Sohn, S. H., Seetharaman, S. V., Bilsel, O., Matthews, C. R., Hart, P. J., Valentine, J. S., and Hayward, L. J. (2009) Metal deficiency increases aberrant hydrophobicity of mutant superoxide dismutases that cause amyotrophic lateral sclerosis. J. Biol. Chem. 284, 27746–27758
45. Steinebach, O. M., and Wolterbeek, H. T. (1993) Effects of zinc on rat hepatoma HTC cells and primary cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 118, 245–254
46. Lemire, J., Mailloux, R., and Appanna, V. D. (2008) Zinc toxicity alters mitochondrial metabolism and leads to decreased ATP production in hepatocytes. J. Appl. Toxicol. 28, 175–182
47. Rakhit, R., Cunningham, P., Furtos-Matei, A., Dahan, S., Qi, X. F., Crow, J. P., Cashman, N. R., Konjelewski, L. H., and Chakrabarty, A. (2002) Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 277, 47551–47556
48. Richardson, J. S., and Richardson, D. C. (2002) Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc. Natl. Acad. Sci. U.S.A. 99, 2754–2759
49. Valentine, J. S., and Hart, P. J. (2003) Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 100, 3617–3622
50. Pickles, S., Destroismaisons, L., Peyrard, S. L., Cadot, S., Rouleau, G. A., Brown, R. H., Jr., Julien, J. P., Arbour, N., and Vande Velde, C. (2013) Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum. Mol. Genet. 22, 3947–3959
51. Pokrishchevsky, E., Grad, L. I., Yousefi, M., Wang, J., Mackenzie, I. R., and Cashman, N. R. (2012) Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 7, e35050
52. Coelho, T., Maia, L. F., da Silva, A. M., Cruz, M. W., Planté-Bordeneuve, V., Suhr, O. B., Conceição, I., Schmidt, H. H., Trigo, P., Kelly, J. W., Labaudinière, R., Chan, J., Packman, J., and Grogan, D. R. (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polynuropathy. J. Neurol. 260, 2802–2814
53. Greenfield, N. J. (2006) Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc. 1, 2876–2890